Menu Search
Equities

Carisma Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
W2J:STU

Carisma Therapeutics Inc

Actions
  • Price (EUR)0.1278
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-73.17%
  • Beta1.8890
Data delayed at least 15 minutes, as of Oct 10 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

  • Revenue in USD (TTM)52.63m
  • Net income in USD8.04m
  • Incorporated2008
  • Employees46.00
  • Location
    Carisma Therapeutics Inc3675 Market Street, Suite 401PHILADELPHIA 19104United StatesUSA
  • Phone+1 (267) 491-6422
  • Fax+1 (617) 858-0911
  • Websitehttps://sesenbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CARM:PKC since
announced		Transaction
value
OrthoCellix IncDeal completed23 Jun 202523 Jun 2025Deal completed-89.61%--
Data delayed at least 15 minutes, as of Feb 06 2026 20:39 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.